
==== Front
Clin Respir J
Clin Respir J
10.1111/(ISSN)1752-699X
CRJ
The Clinical Respiratory Journal
1752-6981
1752-699X
John Wiley and Sons Inc. Hoboken

10.1111/crj.70008
CRJ70008
CRJ-LE-02-2024-104
Letter to the Editor
Letter to the Editor
Atezolizumab‐Induced Immune‐Related Pneumonia on Rounded Atelectasis
Yanagisawa Satoru https://orcid.org/0000-0003-3895-5518
1 yngsw-0829@umin.org

Yui Takaya 1
Takechi Hiroki 1
Wasamoto Satoshi 1
1 Department of Respiratory Medicine Saku Central Hospital Advanced Care Center Nagano Japan
* Correspondence:
Satoru Yanagisawa (yngsw-0829@umin.org)

03 9 2024
9 2024
18 9 10.1111/crj.v18.9 e7000816 2 2024
22 8 2024
© 2024 The Author(s). The Clinical Respiratory Journal published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

asbestos exposure
atezolizumab
immune‐related adverse events
rounded atelectasis
small‐cell lung cancer
source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:03.09.2024
Funding: The authors received no specific funding for this work.
==== Body
pmcDear editor:

An 82‐year‐old man with a heavy smoking history (35 pack‐years) was diagnosed with right upper lung small cell lung cancer (extensive‐disease, cT1cN3M1c: cStage IVB, LYM, OSS, HEP) in June 2023. He was a retired electrician who had been exposed to construction dust and asbestos fibers for decades. Chest computed tomography (CT) revealed partially calcified pleural plaques and posterior left lower lobe rounded atelectasis (RA) with “comet tail sign” [1] (Figure 1A,B). Retrospectively, the RA appeared to remain the same shape and size since 2017. Positron emission tomography revealed 18F‐fluorodeoxyglucose uptake in the right upper lobe primary tumor, but not in the pleural plaque or RA (Figure 1C–E). Subsequently, the patient was treated with carboplatin/etoposide plus atezolizumab as first‐line chemotherapy in July 2023. Soon after atezolizumab infusion, he developed a transient fever; thereafter, he gradually complained of worsening dyspnea on exertion, with mild desaturation. On day 9 after chemotherapy induction, chest CT showed a new‐onset consolidative shadow on the left lower lung that appeared around the preexisting RA (Figure 2A,B). The laboratory test results, including infectious serology and culture results, were unremarkable. Additional inflammatory serologies (antinuclear and antineutrophil cytoplasmic antibodies) were negative. Due to hypoxemia, further diagnostic studies, such as bronchoscopy, could not be conducted. We suspected that the lesion was consistent with atezolizumab‐induced interstitial lung disease (immune‐related adverse event [irAE]) and started intravenous prednisolone (40 mg daily). After the initiation of steroid treatment, his hypoxemia and lung shadow were almost completely cleared (Figure 2C,D), which supported the diagnosis of irAE pneumonia in RA. We decided to refrain from atezolizumab treatment and continued carboplatin/etoposide therapy alone without recurrence of irAEs.

FIGURE 1 Computed tomography shows a partially calcified pleural plaque and left lower lobe subpleural rounded atelectasis (A and B). Positron emission tomography revealed that 18F‐fluorodeoxyglucose uptake was avid only in the right upper lobe nodule and not in the rounded atelectasis (C–E).

FIGURE 2 Clinical course of computed tomography findings. An exaggerated consolidative shadow around the rounded atelectasis appeared after atezolizumab treatment (A, B), which cleared after steroid treatment (C, D).

RA [2], also known as “folded lung” or “Blesovsky's syndrome,” is a subtype of lung atelectasis caused by invagination of the redundant visceral pleura [3]. Although most RA are believed to be associated with asbestos lung exposure [4], it is sometimes difficult to differentiate RA from other asbestos exposure‐associated malignant diseases such as lung cancer and malignant pleural mesothelioma [5]. RA usually maintains the same volume and even shrinks on serial scans [4, 5, 6], which supports the benign feature of the lesion and justifies careful follow‐up without intervention. However, there are some reports of RA that gradually enlarge and eventually necessitate surgical biopsy or excision [7]. Although the precise mechanism of RA enlargement is yet to be elucidated, persistent chronic pleural inflammation may be associated. In our case, subpleural consolidation around the RA expanded after the initiation of atezolizumab treatment, and it is possible that the pleural damage around the RA contributed to the occurrence of irAE pneumonia. Sakata et al. reported nivolumab‐induced severe interstitial pneumonia that occurred after talc pleurodesis [8]. They speculated that nivolumab may have exaggerated talc‐induced damage to pleural mesothelial cells, and that chemical inflammation eventually resulted in severe interstitial pneumonia. Although asbestos‐associated RA is usually considered an old inflammatory change, it may be a latent stage with the potential to flare with the use of immune checkpoint inhibitors (ICIs).

In conclusion, this was a case of atezolizumab‐induced irAE pneumonia, which occurred in a patient with RA. As asbestos exposure is associated with RA, it is important to appropriately diagnose drug‐induced pneumonia, which may exaggerate pre‐existing RA. In addition, RA‐associated pleural inflammation may become apparent upon ICIs treatment.

Author Contributions

Satoru Yanagisawa and Satoshi Wasamoto conceived the study and drafted the manuscript. Hiroki Takechi and Takaya Yui were involved in the discussion and manuscript preparation.

Consent

All authors reviewed this manuscript and agreed to submit this manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

We would like to thank Editage (www.editage.jp) for English language editing.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.
==== Refs
References

1 V. A. Partap , “The Comet Tail Sign,” Radiology 213 , no. 2 (1999): 553–554, 10.1148/radiology.213.2.r99nv08553.10551240
2 R. Hanke , “Round Atelectasis (Spherical and Cylindrical). Contribution to the Differential Diagnosis of Intrapulmonary Round Foci,” Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 114 , no. 2 (1971): 164–183.5102457
3 L. Dernevik and P. Gatzinsky , “Pathogenesis of Shrinking Pleuritis With Atelectasis—“Rounded Atelectasis”,” European Journal of Respiratory Diseases 71 , no. 4 (1987): 244–249.3691681
4 G. Hillerdal , “Rounded Atelectasis. Clinical Experiences of 74 Patients,” Chest 95 , no. 4 (1989): 836–841, 10.1378/chest.95.4.836.2924612
5 G. T. Stathopoulos , M. T. Karamessini , A. E. Sotiriadi , and V. G. Pastromas , “Rounded Lung Atelectasis,” Respiratory Medicine 99 , no. 5 (2005): 615–623, 10.1016/j.rmed.2004.10.003.15823460
6 L. Azour , T. Billah , M. M. Salvatore , et al., “Causative Factors, Imaging Findings, and CT Course of Round Atelectasis,” Clinical Imaging February 2018 , no. 50 (2018): 250–257, 10.1016/j.clinimag.2018.04.008.
7 S. P. Silverman and P. L. Marino , “Unusual Case of an Enlarged Pulmonary Mass,” Chest 91 , no. 3 (1987): 457–458, 10.1378/chest.91.3.457.3816324
8 S. Sakata , Y. Matsuoka , K. Kawahara , et al., “Severe Interstitial Pneumonia Associated With Anti‐PD‐1 Immune Checkpoint Antibodies After Talc Slurry Pleurodesis,” Respiratory Investigation 56 , no. 2 (2018): 195–198, 10.1016/j.resinv.2017.11.006.29548660
